Figure 1

Certolizumab pegol inhibits TNFα-induced adhesion molecule expression on human dermal microvascular endothelial cells. E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are expressed on human dermal microvascular endothelial cells (HMVECs), inhibited by certolizumab pegol. Cell surface ELISAs were performed to determine the peak expression time of each adhesion molecule on HMVECs induced by TNFα (25 ng/ml). (A) E-selectin, (B) ICAM-1, and (C) VCAM-1 expression is significantly greater on TNFα-stimulated HMVECs compared with the nonstimulated (NS) group. HMVEC expression of E-selectin peaks at 6 hours, while ICAM-1 and VCAM-1 peak at 24 hours (*P < 0.05). Peak expression time points for each adhesion molecule were then used to examine whether certolizumab pegol can inhibit TNFα adhesion molecule induction on HMVECs. (D) E-selectin, (E) ICAM-1, and (F) VCAM-1 expression on HMVECs was stimulated with TNFα (25 ng/ml) in the presence or absence of different concentrations of certolizumab pegol (0.0001 to 10 μg/ml) or mouse-IgG (Ms-Ig) control for 6 hours for E-selectin and for 24 hours for ICAM-1 and VCAM-1 expression, when ECs protein lysates were collected. (G), (H) Western blot results indicate that E-selectin, ICAM-1 and VCAM-1 expression are entirely blocked by higher concentrations of certolizumab pegol (0.1 to 10 μg/ml). Blots are representative of three samples. The results are shown as the fold change of treatment samples to the NS group ± standard error of the mean. n, number of experiments.